Cargando…

COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter

Experts have forewarned about the coronavirus disease 2019 (COVID‐19) pandemic environment fomenting the rising incidence of alcohol use disorder (AUD) and alcohol‐associated liver disease (ALD). We performed a cross‐sectional study of ALD at our liver transplantation (LT) center, located in the ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutledge, Stephanie M., Schiano, Thomas D., Florman, Sander, Im, Gene Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013370/
https://www.ncbi.nlm.nih.gov/pubmed/34533000
http://dx.doi.org/10.1002/hep4.1706
_version_ 1783673486673182720
author Rutledge, Stephanie M.
Schiano, Thomas D.
Florman, Sander
Im, Gene Y.
author_facet Rutledge, Stephanie M.
Schiano, Thomas D.
Florman, Sander
Im, Gene Y.
author_sort Rutledge, Stephanie M.
collection PubMed
description Experts have forewarned about the coronavirus disease 2019 (COVID‐19) pandemic environment fomenting the rising incidence of alcohol use disorder (AUD) and alcohol‐associated liver disease (ALD). We performed a cross‐sectional study of ALD at our liver transplantation (LT) center, located in the initial U.S. epicenter, New York City. Centered around the “stay at home” order date in New York state, March 22, 2020, we defined three time periods: “pre‐COVID” (January 1, 2020‐March 21, 2020), “COVID‐quarantine” (March 22, 2020‐April 22, 2020), and “declining‐COVID” (April 23, 2020‐August 25, 2020). We found a 62% increase in interhospital patient transfers for ALD from pre‐COVID (20 of 93, 21%) to the declining‐COVID period (43 of 127, 34%). Our inpatient liver census with ALD also increased: 38% pre‐COVID, 45% COVID‐quarantine, and 49% declining‐COVID. Among 30 patients with severe alcoholic hepatitis (AH) not responding to medical therapy since March 22, 2020, 9 underwent early LT for AH (16% of the total number of early LT during our 8‐year program). Three of 9 early‐LT recipients reported specific COVID‐related stressors. All 25 previous LT recipients with established abstinence pre‐COVID maintained abstinence at follow‐up visits during the declining‐COVID period. Of the 6 recipients with sustained alcohol use within 6 months before March 22, 2020, half regained abstinence during the declining‐COVID period. Our findings help confirm the predictions of rising AUD and ALD as an immediate consequence of the COVID‐19 pandemic. This aftershock particularly affected ethnically diverse patients with ALD with high inpatient mortality, reflecting the disproportionate impact of COVID‐19 on underserved and minority populations. Alcohol relapse did not occur in long‐term early LT for AH recipients during the time of COVID‐19. This lends further support to AH being a viable indication for LT, with recipients able to demonstrate ongoing resilience in the face of this unprecedented universal stressor.
format Online
Article
Text
id pubmed-8013370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80133702021-04-01 COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter Rutledge, Stephanie M. Schiano, Thomas D. Florman, Sander Im, Gene Y. Hepatol Commun Original Articles Experts have forewarned about the coronavirus disease 2019 (COVID‐19) pandemic environment fomenting the rising incidence of alcohol use disorder (AUD) and alcohol‐associated liver disease (ALD). We performed a cross‐sectional study of ALD at our liver transplantation (LT) center, located in the initial U.S. epicenter, New York City. Centered around the “stay at home” order date in New York state, March 22, 2020, we defined three time periods: “pre‐COVID” (January 1, 2020‐March 21, 2020), “COVID‐quarantine” (March 22, 2020‐April 22, 2020), and “declining‐COVID” (April 23, 2020‐August 25, 2020). We found a 62% increase in interhospital patient transfers for ALD from pre‐COVID (20 of 93, 21%) to the declining‐COVID period (43 of 127, 34%). Our inpatient liver census with ALD also increased: 38% pre‐COVID, 45% COVID‐quarantine, and 49% declining‐COVID. Among 30 patients with severe alcoholic hepatitis (AH) not responding to medical therapy since March 22, 2020, 9 underwent early LT for AH (16% of the total number of early LT during our 8‐year program). Three of 9 early‐LT recipients reported specific COVID‐related stressors. All 25 previous LT recipients with established abstinence pre‐COVID maintained abstinence at follow‐up visits during the declining‐COVID period. Of the 6 recipients with sustained alcohol use within 6 months before March 22, 2020, half regained abstinence during the declining‐COVID period. Our findings help confirm the predictions of rising AUD and ALD as an immediate consequence of the COVID‐19 pandemic. This aftershock particularly affected ethnically diverse patients with ALD with high inpatient mortality, reflecting the disproportionate impact of COVID‐19 on underserved and minority populations. Alcohol relapse did not occur in long‐term early LT for AH recipients during the time of COVID‐19. This lends further support to AH being a viable indication for LT, with recipients able to demonstrate ongoing resilience in the face of this unprecedented universal stressor. John Wiley and Sons Inc. 2021-04-07 /pmc/articles/PMC8013370/ /pubmed/34533000 http://dx.doi.org/10.1002/hep4.1706 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Rutledge, Stephanie M.
Schiano, Thomas D.
Florman, Sander
Im, Gene Y.
COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
title COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
title_full COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
title_fullStr COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
title_full_unstemmed COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
title_short COVID‐19 Aftershocks on Alcohol‐Associated Liver Disease: An Early Cross‐Sectional Report From the U.S. Epicenter
title_sort covid‐19 aftershocks on alcohol‐associated liver disease: an early cross‐sectional report from the u.s. epicenter
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013370/
https://www.ncbi.nlm.nih.gov/pubmed/34533000
http://dx.doi.org/10.1002/hep4.1706
work_keys_str_mv AT rutledgestephaniem covid19aftershocksonalcoholassociatedliverdiseaseanearlycrosssectionalreportfromtheusepicenter
AT schianothomasd covid19aftershocksonalcoholassociatedliverdiseaseanearlycrosssectionalreportfromtheusepicenter
AT flormansander covid19aftershocksonalcoholassociatedliverdiseaseanearlycrosssectionalreportfromtheusepicenter
AT imgeney covid19aftershocksonalcoholassociatedliverdiseaseanearlycrosssectionalreportfromtheusepicenter